Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 3;7(6):e2413955.
doi: 10.1001/jamanetworkopen.2024.13955.

Delays to Antibiotics in the Emergency Department and Risk of Mortality in Children With Sepsis

Affiliations

Delays to Antibiotics in the Emergency Department and Risk of Mortality in Children With Sepsis

Roni D Lane et al. JAMA Netw Open. .

Erratum in

  • Error in Results.
    [No authors listed] [No authors listed] JAMA Netw Open. 2024 Dec 2;7(12):e2455269. doi: 10.1001/jamanetworkopen.2024.55269. JAMA Netw Open. 2024. PMID: 39680413 Free PMC article. No abstract available.

Abstract

Importance: Pediatric consensus guidelines recommend antibiotic administration within 1 hour for septic shock and within 3 hours for sepsis without shock. Limited studies exist identifying a specific time past which delays in antibiotic administration are associated with worse outcomes.

Objective: To determine a time point for antibiotic administration that is associated with increased risk of mortality among pediatric patients with sepsis.

Design, setting, and participants: This retrospective cohort study used data from 51 US children's hospitals in the Improving Pediatric Sepsis Outcomes collaborative. Participants included patients aged 29 days to less than 18 years with sepsis recognized within 1 hour of emergency department arrival, from January 1, 2017, through December 31, 2021. Piecewise regression was used to identify the inflection point for sepsis-attributable 3-day mortality, and logistic regression was used to evaluate odds of sepsis-attributable mortality after adjustment for potential confounders. Data analysis was performed from March 2022 to February 2024.

Exposure: The number of minutes from emergency department arrival to antibiotic administration.

Main outcomes and measures: The primary outcome was sepsis-attributable 3-day mortality. Sepsis-attributable 30-day mortality was a secondary outcome.

Results: A total of 19 515 cases (median [IQR] age, 6 [2-12] years) were included. The median (IQR) time to antibiotic administration was 69 (47-116) minutes. The estimated time to antibiotic administration at which 3-day sepsis-attributable mortality increased was 330 minutes. Patients who received an antibiotic in less than 330 minutes (19 164 patients) had sepsis-attributable 3-day mortality of 0.5% (93 patients) and 30-day mortality of 0.9% (163 patients). Patients who received antibiotics at 330 minutes or later (351 patients) had 3-day sepsis-attributable mortality of 1.2% (4 patients), 30-day mortality of 2.0% (7 patients), and increased adjusted odds of mortality at both 3 days (odds ratio, 3.44; 95% CI, 1.20-9.93; P = .02) and 30 days (odds ratio, 3.63; 95% CI, 1.59-8.30; P = .002) compared with those who received antibiotics within 330 minutes.

Conclusions and relevance: In this cohort of pediatric patients with sepsis, 3-day and 30-day sepsis-attributable mortality increased with delays in antibiotic administration 330 minutes or longer from emergency department arrival. These findings are consistent with the literature demonstrating increased pediatric sepsis mortality associated with antibiotic administration delay. To guide the balance of appropriate resource allocation with time for adequate diagnostic evaluation, further research is needed into whether there are subpopulations, such as those with shock or bacteremia, that may benefit from earlier antibiotics.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Scott reported receiving grants from the Agency for Healthcare Research and Quality during the conduct of the study. Dr Balamuth reported receiving grants from the National Institutes of Health and receiving a combination of federal and foundational grants to study sepsis and other infectious emergencies outside the submitted work. Dr Huskins reported receiving personal fees from Pfizer and ADMA Biologics, and stock from Pfizer, Bristol Myers Squibb, and Zimmer Biomet outside the submitted work. Dr Horvat reported receiving grants from the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke outside the submitted work. Dr Hueschen reported receiving travel and lodging for Improving Pediatric Sepsis Outcomes sepsis conferences from the Children’s Hospital Association during the conduct of the study. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Time to Antibiotics and 3-Day Sepsis-Attributable Mortality Among Children With Sepsis
Graph shows piecewise regression analysis evaluating the association of time to antibiotic administration with 3-day sepsis-attributable mortality. Time is represented in 30-minute increments, and the number of patients at each time point is denoted in parentheses. The P value represents the change in the unadjusted slope from preinflection to postinflection point (dashed vertical line).
Figure 2.
Figure 2.. Time to Antibiotics and 3-Day Sepsis-Attributable Mortality Among Children With Bacteremia and Sepsis
Graph shows piecewise regression analysis evaluating the association of time to antibiotic administration with 3-day sepsis-attributable mortality in patients with sepsis and bacteremia. Time is represented in 30-minute increments, and the number of patients at each time point is denoted in parentheses. The P value represents the change in the unadjusted slope from preinflection to postinflection point (dashed vertical line).

Comment in

Similar articles

Cited by

References

    1. Kissoon N, Reinhart K, Daniels R, Machado MFR, Schachter RD, Finfer S. Sepsis in children: global implications of the World Health Assembly resolution on sepsis. Pediatr Crit Care Med. 2017;18(12):e625-e627. doi:10.1097/PCC.0000000000001340 - DOI - PubMed
    1. Rudd KE, Johnson SC, Agesa KM, et al. . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7 - DOI - PMC - PubMed
    1. Weiss SL, Fitzgerald JC, Pappachan J, et al. ; Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network . Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147-1157. doi:10.1164/rccm.201412-2323OC - DOI - PMC - PubMed
    1. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. 2018;6(3):223-230. doi:10.1016/S2213-2600(18)30063-8 - DOI - PubMed
    1. Balamuth F, Weiss SL, Neuman MI, et al. . Pediatric severe sepsis in U.S. children’s hospitals. Pediatr Crit Care Med. 2014;15(9):798-805. doi:10.1097/PCC.0000000000000225 - DOI - PMC - PubMed

Publication types

Substances